Lake Street Advisors Group LLC Sells 39,768 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Lake Street Advisors Group LLC cut its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 59.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,598 shares of the company’s stock after selling 39,768 shares during the quarter. Lake Street Advisors Group LLC’s holdings in Hims & Hers Health were worth $667,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Creative Planning increased its stake in shares of Hims & Hers Health by 18.1% in the third quarter. Creative Planning now owns 25,925 shares of the company’s stock worth $478,000 after buying an additional 3,979 shares during the period. International Assets Investment Management LLC bought a new position in shares of Hims & Hers Health during the third quarter valued at about $6,790,000. Diversify Advisory Services LLC increased its holdings in Hims & Hers Health by 14.9% during the 3rd quarter. Diversify Advisory Services LLC now owns 51,828 shares of the company’s stock valued at $955,000 after purchasing an additional 6,706 shares during the period. Robeco Institutional Asset Management B.V. bought a new position in Hims & Hers Health during the 3rd quarter valued at approximately $604,000. Finally, QRG Capital Management Inc. lifted its holdings in Hims & Hers Health by 3.9% in the 3rd quarter. QRG Capital Management Inc. now owns 162,029 shares of the company’s stock worth $2,985,000 after buying an additional 6,077 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on HIMS shares. Citigroup lifted their price target on shares of Hims & Hers Health from $25.00 to $27.00 and gave the company a “sell” rating in a report on Tuesday. Morgan Stanley cut Hims & Hers Health from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Truist Financial increased their target price on Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a research report on Wednesday. Needham & Company LLC increased their price objective on Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and an average target price of $35.71.

Insider Activity at Hims & Hers Health

In other news, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total value of $7,465,960.29. Following the completion of the transaction, the chief executive officer now directly owns 97,687 shares in the company, valued at $5,692,221.49. This trade represents a 56.74 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Soleil Boughton sold 268,932 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the sale, the insider now directly owns 169,803 shares of the company’s stock, valued at approximately $4,712,033.25. This represents a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,097,578 shares of company stock worth $38,080,320 over the last three months. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Stock Down 1.4 %

Shares of HIMS opened at $41.30 on Friday. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98. The stock has a fifty day simple moving average of $36.19 and a two-hundred day simple moving average of $26.46. The company has a market capitalization of $9.02 billion, a PE ratio of 93.85 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.